The zNose® MRSA test is a non-invasive breath test for markers of Staphylococcus aureus, which may predict the probability of bacterial organisms in the anterior nares, throat and respiratory tract, wounds, and anus and therefore be able to replace or supplement current active Methicillin Resistant Staphylococcus Aureus (MRSA) surveillance efforts. It consists of:

• A collection apparatus for collection of volatile compounds from suspected infection sites onto a sorbent trap or Tedlar bag, as well as for the collection of a separate sample of room air.
• Analysis of the volatile organic compounds from suspected infection sites and room air by short acoustic wave gas chromatography.
• Interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of Staphylococcus aureus infection and colonization.

This study will test the hypothesis that we can identify the presence of MRSA by sampling the "head space" above culture media of anterior nare samples provided by patients with MRSA. Additionally, this study will test the hypothesis that we can identify the presence of MRSA by sampling air exhaled through the nostrils (nasal exhalant).

Inclusion Criteria:

• Suspicion of staphylococcus aureus infection or colonization
• Able to give samples for zNose® analysis

Exclusion Criteria:

• Inability to provide sample for zNose® analysis

Patients will be selected upon suspicion of MRSA or MSSA infection or colonization. Increased concentration will be give to selection of persons from the following high risk groups:

• It has been documented that the patient has been previously discharged from a general acute care hospital within 30 days prior to the current hospital admission.
• The patient will be admitted to an intensive care unit or burn unit of the hospital.
• The patient receives inpatient dialysis treatment.
• The patient is being transferred from a skilled nursing facility